Therefore, in preclinical studies, attempts were made to combine bicarbonate (neutralizing lactic acid) with anti-CTLA-4, anti-PD-1 or ACT, a strategy that greatly improved the efficacy of tumor immunotherapy (Pilon-Thomas et al., 2016). This evidence concerns the gene PDCD1 and neoplasm.